A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

Growth stocks have soared this year as investors bet on an improving economic environment and technology players involved in ...

The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in ...

At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...

After breaking the program record for most career three-pointers made at the College Hill Classic this weekend, senior Kino ...

FLRG focuses on large- and mid-cap US companies, emphasizing valuation and quality, among others. Read why FLRG ETF is a ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.

Alexandria Real Estate Equities (ARE), a company credited with developing several science campuses in San Diego, recently ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), retaining the price target of $970.00. Don't Miss our Black Friday Offers: David Risinger ...